ZNTL Key Statistics, Chart & Performance
The current stock price of ZNTL is 2.95 USD. In the past month the price increased by 110.71%. In the past year, price increased by 32.88%.
ZNTL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ZNTL. When comparing the yearly performance of all stocks, ZNTL is one of the better performing stocks in the market, outperforming 93.25% of all stocks.
ZNTL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZNTL. ZNTL has a great financial health rating, but its profitability evaluates not so good.
ZNTL Financial Highlights
Over the last trailing twelve months ZNTL reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS increased by 25.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.48% | ||
| ROE | -58.86% | ||
| Debt/Equity | 0 |
ZNTL Forecast & Estimates
15 analysts have analysed ZNTL and the average price target is 5.42 USD. This implies a price increase of 83.69% is expected in the next year compared to the current price of 2.95.
For the next year, analysts expect an EPS growth of 18.41% and a revenue growth -100% for ZNTL
ZNTL Ownership
ZNTL Latest News, Press Relases and Analysis
About ZNTL
Company Profile
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in San Diego, California and currently employs 166 full-time employees. The company went IPO on 2020-04-03. The firm is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The firm is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Company Info
ZENTALIS PHARMACEUTICALS INC
10275 Science Center Drive, Suite 200
San Diego CALIFORNIA 10018 US
CEO: Anthony Y. Sun
Employees: 166
Phone: 18582634333
ZENTALIS PHARMACEUTICALS INC / ZNTL FAQ
What does ZENTALIS PHARMACEUTICALS INC do?
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in San Diego, California and currently employs 166 full-time employees. The company went IPO on 2020-04-03. The firm is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The firm is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
What is the stock price of ZENTALIS PHARMACEUTICALS INC today?
The current stock price of ZNTL is 2.95 USD. The price increased by 2.79% in the last trading session.
What is the dividend status of ZENTALIS PHARMACEUTICALS INC?
ZNTL does not pay a dividend.
What is the ChartMill rating of ZENTALIS PHARMACEUTICALS INC stock?
ZNTL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of ZNTL stock?
ZENTALIS PHARMACEUTICALS INC (ZNTL) operates in the Health Care sector and the Biotechnology industry.
Is ZENTALIS PHARMACEUTICALS INC (ZNTL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZNTL.
Can you provide the upcoming earnings date for ZENTALIS PHARMACEUTICALS INC?
ZENTALIS PHARMACEUTICALS INC (ZNTL) will report earnings on 2026-03-24, after the market close.